<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003771</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066897</org_study_id>
    <secondary_id>ROC-HABITS</secondary_id>
    <secondary_id>EORTC-10992</secondary_id>
    <secondary_id>IBCSG-17-98</secondary_id>
    <secondary_id>SBG-HABITS</secondary_id>
    <secondary_id>EU-98077</secondary_id>
    <nct_id>NCT00003771</nct_id>
  </id_info>
  <brief_title>Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer</brief_title>
  <official_title>Protocol for Randomized Clinical Study Concerning Hormonal Replacement Therapy (HRT) After Previous Radical Breast Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Oncologic Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scandinavian Breast Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ETOP IBCSG Partners Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Hormone replacement therapy is effective for relieving symptoms of menopause. It&#xD;
      is not yet known if hormone replacement therapy increases the risk of breast cancer&#xD;
      recurrence in women previously treated for early stage breast cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to determine the risk of breast cancer recurrence in&#xD;
      women with previous early stage breast cancer who are receiving hormone replacement therapy&#xD;
      for menopause symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the safety of hormone replacement therapy, in terms of risk of recurrence, in&#xD;
           women with previously treated, nonrecurrent stage 0-II breast cancer.&#xD;
&#xD;
        -  Compare this regimen vs non-hormonal symptomatic treatment, in terms of quality of life&#xD;
           and risk of death, in this patient population.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified by&#xD;
      center, prior hormone replacement therapy before diagnosis, and concurrent tamoxifen therapy.&#xD;
      Patients are randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive one of the following: Women with an intact uterus whose last&#xD;
           menstrual bleeding has occurred within 2 years receive continuous oral cyclic&#xD;
           estradiol-norethindrone combination comprising estradiol only on days 1-12, estradiol&#xD;
           plus norethindrone on days 13-22, and then estradiol only on days 22-28. Women with an&#xD;
           intact uterus whose last menstrual bleeding occurred more than 2 years prior to study&#xD;
           receive continuous daily oral estradiol-norethindrone combination. Women who have had a&#xD;
           hysterectomy receive continuous daily oral estradiol only.&#xD;
&#xD;
        -  Arm II: Patients receive one or more non-hormonal therapies (e.g., clonidine, beta&#xD;
           blockers, psychological support, physical exercise, acupuncture).&#xD;
&#xD;
      Treatment in both arms continues for 2 years in the absence of disease progression. Patients&#xD;
      may continue their randomized treatment regimen at the discretion of the treating physician.&#xD;
&#xD;
      Quality of life is assessed 3 times during the study and then every two years thereafter.&#xD;
      Gynecological health is assessed at 3 months, 6 months, and one year during the study and&#xD;
      then annually for at least 5 years. Breast cancer is assessed every 6 months for 3 years and&#xD;
      then annually thereafter or at the discretion of the treating physician.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 1,300 patients will be accrued for this study within 5-6 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1997</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Menopausal Symptoms</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic estradiol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norethindrone acetate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  History of stage 0-II breast cancer with no more than 4 involved axillary nodes if&#xD;
             nodal status and number of nodes investigated is known&#xD;
&#xD;
          -  No current evidence of disease&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Positive, negative, or unknown&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Menopausal or perimenopausal&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No active liver disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No prior or concurrent deep vein thrombosis&#xD;
&#xD;
          -  No hereditary traits for deep vein thrombosis&#xD;
&#xD;
          -  No prior or concurrent cerebral stroke&#xD;
&#xD;
          -  No prior or concurrent coronary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No porphyria&#xD;
&#xD;
          -  No other serious disease that would prevent compliance or greatly limit life&#xD;
             expectancy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior hormone replacement therapy (HRT) allowed if stopped no more than 4 weeks after&#xD;
             breast cancer diagnosis and at least 3 months prior to study&#xD;
&#xD;
          -  No prior HRT initiated after breast cancer diagnosis&#xD;
&#xD;
          -  No concurrent hormonal therapy for breast cancer except tamoxifen or toremifene&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior randomization into trials comparing effects of chemotherapy and bilateral&#xD;
             oophorectomy in premenopausal women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Holmberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonas Bergh, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. Rageth, MD, PD</last_name>
    <role>Study Chair</role>
    <affiliation>Breast Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janusz Jaskiewicz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maria Sklodowska-Curie National Research Institute of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>S-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>S-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breast Center</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Brincat M, Muscat Baron Y, Ciantar E. Hormone replacement in women with breast cancer: the HABITS study. Endocrine. 2004 Aug;24(3):255-7. doi: 10.1385/endo:24:3:255.</citation>
    <PMID>15542894</PMID>
  </reference>
  <results_reference>
    <citation>Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J; HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008 Apr 2;100(7):475-82. doi: 10.1093/jnci/djn058. Epub 2008 Mar 25. Erratum In: J Natl Cancer Inst. 2008 May 7;100(9):685. Maenpa, Johanna [corrected to Maenpaa, Johanna].</citation>
    <PMID>18364505</PMID>
  </results_reference>
  <results_reference>
    <citation>Holmberg L, Anderson H; HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet. 2004 Feb 7;363(9407):453-5. doi: 10.1016/S0140-6736(04)15493-7.</citation>
    <PMID>14962527</PMID>
  </results_reference>
  <verification_date>July 2001</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>menopausal symptoms</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>breast cancer in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone Acetate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

